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TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS 1
This paper from the Tuberculosis Chemotherapy Centre, Madras, presents the results
of a study designedprimarily ( ) to assess the efficacy of two preparations–Tab. Aneurin. Co.
(a vitamin B compound not containing pyridoxine) and glutamic acid–in preventing the
development of peripheral neuropathy during high-dosage (12.5-15.2 mg/kg) isoniazid
therapy for pulmonary tuberculosis, and (b) to compare the therapeutic efficacy, once
isoniazid neuropathy has developed, of Tab. Aneurin. Co., administered at twice the pro-
phylactic dosage, and a vitamin-B-complex preparation containing a small amount of
pyridoxine (amounting to 6 mg daily).
Tab. Aneurin. Co. was found to be ineffective in preventing peripheral neuropathy,
which occurred in five of the 18 patients receiving this preparation, as compared with
six of the 18 who received a placebo, calcium gluconate. Glutamic acid appeared to have
some prophylactic effect, since only two of the 19 patients receiving it developed the neuro-
pathy, but the difference between the frequency in the glutamic series and that in the
placebo series did not attain statistical significance.
As to the therapeutic efficacy of the two vitamin B preparations, Tab. Aneurin. Co.,
at twice the prophylactic dosage, did not prevent the progression of the neuropathy in
jive out of seven patients, whereas improvement occurred in eight of the nine patients who
received the vitamin-B-complex preparation containing the small amount of pyridoxine.
This study has confirmed that the frequency of peripheral neuropathy is significantly
higher among slow than among rapid inactivators of isoniazid and has indicated that the
therapeutic response of the tuberculosis is not materially affected by increasing the dosage
of isoniazid from 7.8-9.6 mg/kg (the dosage used in a previous study) to 12.5-15.2 mg/kg.
*This paper will also be published, in Spanish, in the
Boletin de la Oficina Sanitaria Panamericana.
1 The Centre is under the joint auspices of the Indian
Council of Medical Research (ICMR), the Madras State
Government, the World Health Organization (WHO) and
the Medical Research Council of Great Britain (MRC).
The members of the scientific staff of the Centre with major
responsibility for the work reported here are: Dr Wallace
Fox (WHO), Senior Medical Officer, succeeded by Dr Hugh
Stott in November 1960; Dr C. V. Ramakrishnan (ICMR)
and Dr S. Velu (Madras Government), Medical Officers;
Dr S. Devadatta (ICMR), Assistant Medical Officer;
  Dr J. H. Angel (WHO), Medical Officer, succeeded by
Dr J. J. Y. Dawson; Dr A. L. Bhatia (ICMR) and Dr J. B.
Selkon (WHO), Bacteriologists; Dr P. R. J. Gangadharam
(ICMR ) ,   Assistant Bacteriologist; Mr D. V. Krishnamurthy
(ICMR), Biochemist; Mr C. Narayanan Nair (ICMR) and
Mr T. V. Subbaiah (ICMR), Laboratory Research Assis-
tants; Mr K. L. Thomas (WHO), Laboratory Technician;
Mr S. Radhakrishna (Madras Government), Senior Statisti-
cian; Mr K. Ramachandran (ICMR) and Mr P. R. Soma-
sundaram (ICMR), Statisticians; and Mr B. Janardhanam
(ICMR), Senior Assistant Statistician.
The research of the Centre is guided by a Project Commit-
tee consisting of three ICMR representatives (Dr P. V. Ben-
jami , Convener, Dr J. Frimodt-Møller and Dr K. S. Sanjivi),
the Director of the ICMR (Dr C. G. Pandit), the Director of
Medical Services, Madras State (Dr V. R. Thayumanaswamy,
succeeded by Dr A. B. Marikar), a WHO representative
(appointed for each meeting), an MRC representative
(appointed for each meeting) and the Senior Medical Officer
of the Centre. The joint secretaries were Mrs K. Daniels and
Mr B. S. Verma, succeeded by Mr D. Chakravarti and
Mr V. S. Talwar. The MRC, through its Tuberculosis
Research Unit, is responsible for the scientific direction of
the research in accordance with plans prepared by the
Project Committee.
The patients in the present study were referred to the
Centre from the Government Tuberculosis Institute, Madras
(Director: Dr M. A. Hamid) and the Corporation Tubercu-
losis Clinic, Pulianthope (Medical Officer in Charge:
Dr V. S. Selvapathy).
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I. INTRODUCTION
A previous report from the Tuberculosis Chemo-
therapy Centre, Madras, showed that isoniazid
given by itself in moderate dosage (7.8-9.6 mg/kg
body-weight) once daily was more effective than the
same daily dosage given in two doses, but was less
effective than a standard combination of isoniazid
plus PAS (Tuberculosis Chemotherapy Centre, 1960).
It was therefore considered important to investigate
whether an even larger single daily dose of isoniazid
could approach the efficacy of the combined
regimen. Unfortunately, peripheral neuropathy
occurred in 18 % of 74 patients receiving isoniazid in
the moderate dosage (7.8-9.6 mg/kg) when this was
given once daily. A still larger dosage of isoniazid
would therefore be unsuitable unless some means of
preventing toxicity could be found.
Various substances have been tried in the pro-
phylaxis of isoniazid neuropathy. Pyridoxine has
been used successfully by Biehl & Vilter (1954) and
Tchertkoff et al. (1956), but it has been suggested
that in high dosage it might interfere with the anti-
tuberculous properties of the isoniazid (East African/
British Medical Research Council Isoniazid Investi-
gation, 1960). It was for this reason, and also
because the prophylactic use of pyridoxine, in the
usual dosage of 100 mg daily or more, greatly
increases the cost of treatment with isoniazid, that
other possible prophylactics have been investigated.
It has been reported that glutamic acid prevents
the development of neuropathy (Schettino, 1953;
Almeida et al., 1960). Turner (1961) l found that a
vitamin-B-complex preparation not containing pyri-
doxine was successful in the treatment of peripheral
n ur pathy due to a high dosage of isoniazid even
when the latter was continued.
In this study glutamic acid and a vitamin-B-corn-
plex preparation not containing pyridoxine (Tab.
Aneurin. Co.), similar to that found to be effective
therapeutically by Turner, have been tested for their
prophylactic efficacy. In addition, the therapeutic
effect, once isoniazid neuropathy has developed, of
Tab. Aneurin. Co. and of a vitamin-B-complex pre-
paration containing pyridoxine, shown earlier at
the Centre to have a beneficial effect on peripheral
neuropathy (Devadatta et al., 1960), has been
tested.
OBJECTS OF THE STUDY
1. (a) To assess the efficacy of two preparations
–namely, glutamic acid and Tab. Aneurin. Co.
–in the prevention of toxicity due to high-
dosage isoniazid therapy.
(b) to investigate in patients with peripheral
neuropathy the therapeutic effectiveness of two
supplements-namely, an increased dosage of
Tab. Aneurin. Co. and a vitamin-B-complex
pr paration containing a small amount of
p ridoxine.
2. To assess the frequency of isoniazid peripheral
neuropathy in slow and rapid inactivators of
isoniazid.
3. To obtain preliminary information on the
therapeutic effectiveness of high-dosage isoniazid in
patients with pulmonary tuberculosis.
II. PLAN AND CONDUCT OF THE STUDY
The study was designed to compare the frequency
of isoniazid neuropathy among patients receiving
Tab. Aneurin. Co. or glutamic acid with that among
patients receiving a placebo (calcium gluconate) and
to test the therapeutic effect on the neuropathy of
Tab. Aneurin. Co. as well as a more comprehensive
B-complex preparation. In order to eliminate the
possibility of bias in the diagnosis of peripheral
neuropathy and the assessment of its progress, the
investigation was conducted by the “ double-blind ”
1 Information originally reported by Turner in 1958 in a
personal communication to the Centre.
method. In this way it was ensured that although
th  clinicians knew that isoniazid was being given
they did not know the dosage or rhythm in which it
was being administered, and neither they nor the
health visitors knew the number of the supplements
or their nature or were aware of any subsequent
chang  in them.
PATIENTS
Patients were drawn from the same defined area
in Madras City as in a previous investigation (Tuber-
culosis Chemotherapy Centre, 1960). As before,
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nearly all came from the poorest sections of the
population, and were referred to the Centre from
local tuberculosis clinics where they had attended
with symptoms. In a few instances they were con-
tacts of patients already under treatment at the
Centre.
All patients had bacteriologically confirmed
pulmonary tuberculosis. They were admitted to the
study on the same criteria as those which applied in
previous studies undertaken at the Centre (Tuber-
culosis Chemotherapy Centre, 1959, 1960); in
particular, the patients were aged 12 years or more,
had no clinical evidence of leprosy or diabetes, and
had either received no previous antituberculosis
chemotherapy or had had it for a maximum of two
weeks. In addition, no patient with any evidence of
peripheral neuropathy was admitted to treatment.
The patients were examined clinically with special
attention to the nervous system. Among other
pretreatment investigations were:
1. A full-plate postero-anterior chest radiograph.
2. The examination by direct smear and culture of
a miniium of four sputum specimens; three were
collected overnight in the home (collection speci-
mens) and one was expectorated on demand at the
Centre (spot specimen).
3. Tests of sensitivity to isoniazid and strepto-
mycin on two cultures.
4. The determination of the rate of inactivation of
isoniazid.
Chemotherapy
REGIMENS
All the patients were prescribed high-dosage
isoniazid (12.5-15.2 mg/kg body-weight–see Table 1)
to be taken once daily. The mean daily dosage of
isoniazid at the start of chemotherapy was 13.8
mg/kg. If the patient gained weight at a monthly
examination and moved into a higher weight
category, the dosage was increased; if, however, he
lost weight the dosage was not reduced.
Allocation of prophylactic supplements
Each patient was allocated at random to one of
three supplementary regimens, two being tested for
their prophylactic effect and one being a placebo.
The allocation was made by the statisticians from a
list which was based on random sampling numbers
and which had been incorporated in a series of
numbered sealed envelopes before the start of the
study.The first allocation was made on 26 December
1959 and the last on 9 June 1960. During this period
56 patients were admitted to the study.
Su plements
The three supplement series were:
(a) Tab. Aneurin. Co. (British National For-
mulary), prescribed as three tablets of 0.2 g twice
daily. Each tablet contained 1 mg of aneurine
hydrochloride, 1 mg of riboflavine and 15 mg of
nicotinamide (Aneurin. Co. series).
TABLE 1
DAILY DOSAGE OF ISONIAZID IN RELATION TO BODY-WEIGHT
Body-weight a
lb. kg
Amount
of isoniazid
given daily
(mg)
Number of
patients
(on admission
to treatment)
40-49 18.0-22.4 300 16.7-13.4 1
50-59 22.5-26.9 350 15.6-13.0 2
60-69 27.0-31.5 400 14.8-12.7 7
70-79 31.6-36.0 450 14.2-12.5 17
80-89 36.1-40.6 550 15.2-13.5 13
90-99 40.7-45.1 600 14.7-13.3 11
100-109 45.2-49.6 650 14.4-13.1 1
110-119 49.7-54.2 700 14.1-12.9 2
a The weight was recorded to the nearest lb.
458 TUBERCULOSIS CHEMOTHERAPY CENTRE
(b) l -glutamic acid in a dosage of 5 g, prescribed
as five tablets of 0.5 g twice daily (glutamic series).
(c) Calcium gluconate (the placebo), prescribed
as five tablets of 0.5 g twice daily (calcium series).
Method of dispensing the isoniazid and supplements
The morning dose, consisting of isoniazid and
supplement, was dispensed in a sealed pink packet
and the evening dose, consisting of supplement only,
in a sealed white packet. The patients received a
week’s supply of packets at each weekly visit to the
Centre.
Prescribed duration of treatment
Both the isoniazid and the supplements were
provisionally prescribed for a period of 12 months.
General management
The patients were treated at home and attended
the Centre each week for supplies of medicine. A
surprise visit was paid to the home twice weekly by
a health visitor to check the patient’s stock of drugs
and to collect a specimen of urine. A few patients
who were very ill had their medicine delivered to
the home in the early weeks. All patients were
advised to stop work initially and the majority did
so; only patients feeling really ill took the advice to
rest and most patients were ambulant for much of
the time and were frequently not at home when
surprise visits were paid. Patients were encouraged
to return to work when they were medically fit, but
a number returned to work even before being re-
commended to do so.
Regularity of drug taking
Regularity of drug taking was supervised in two
ways. The stock of sealed packets remaining in the
patient’s possession was counted at the surprise
visits paid to the home by the health visitors and
specimens of urine collected at home and at each
clinic attendance were tested for isoniazid by the
combined naphthoquinone-mercuric chloride (N-M)
test (Gangadharam et al., 1958).
ASSESSMENT AND MANAGEMENT OF
PERIPHERAL NEUROPATHY
Assessment
Any spontaneous complaint suggestive of peripheral
neuropathy was recorded, but patients were not
questioned to elicit symptoms. If symptoms were
reported on more than one occasion a full neuro-
logical examination was carried out and this was
repeated at intervals depending on the severity of
the symptoms. When two of the Centre’s doctors
agreed that one or more physical signs of peripheral
neuropathy were present, the patient was examined
by an independent assessor (Dr J. Chandy,
Dr S. Janaki, Dr C. E. Klontz or Dr K. V. Mathai
of the Christian Medical College, Vellore). When
the assessor confirmed the diagnosis of peripheral
neuropathy a change of supplement was made, but
the dosage of isoniazid remained the same and the
patient was re-examined neurologically at the Centre
at intervals of two weeks. If there was an increase
in the severity of symptoms and the development of
fresh physical signs, confirmed by at least two of the
Centre’s physicians, the peripheral neuropathy was
deemed to have progressed and the supplement was
changed again without recourse to an outside asses-
sor. The same dosage of isoniazid was, however,
ontinued.
Therapeutic supplements for isoniazid neuropathy
Supplements were changed for patients who de-
veloped peripheral neuropathy as shown in Fig. 1.
(a) Patients receiving Tab. Aneurin. Co. (Aneurin.
Co. series) were given a vitamin-B-complex supple-
ment that had previously been found, by Devadatta
et al. (1960), to be effective, prescribed as three tablets
of 0.3 g twice daily; each tablet contained 10 mg of
aneurine hydrochloride, 5 mg of riboflavine, 50 mg
of nicotinamide, 1 mg of pyridoxine, 3 mg of
panthenol and 1 µg of cyanocobalamin (an average
of 10% of riboflavine, pyridoxine and panthenol,
33 % of aneurine hydrochloride and 50 % of cyano-
cobalamin had been added by the manufacturers).
(b) Patients receiving glutamic acid (glutamic
e ies) or calcium gluconate (calcium series) had
their supplements changed to Tab. Aneurin. Co.,
four tablets three times daily, that is, twice the
prophylactic dosage. The extra dose was dispensed
in green packets to be taken at mid-day. If, in spite
of this change of supplement, the neuropathy
advanced, a further change was made and three
tablets twice daily of the vitamin B complex con-
taining pyridoxine referred to above were given.
(c) If the neuropathy progressed on the vitamin-B-
complex supplement, the patients in all three series
were eligible for 300 mg of pyridoxine daily, and 1 g
of streptomycin sulfate daily plus 5 g of PAS sodium
twic  daily instead of the isoniazid.
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MANAGEMENT OF PULMONARY TUBERCULOSIS Radiographic or clinical deterioration warranting a
change of chemotherapy
Routine assessments during treatment
Assessments made at monthly intervals after the
Radiographic deterioration was assessed as des-
start of chemotherapy included (a) measurement ofcribed previously (TuberculosisChemotherapy
the weight, (b) a postero-anterior chest radiograph,Centre, 1960). In brief, the full radiographic series of
(c) the examination of two overnight collectionany sputum-positive patient who was considered by
specimens of sputum by smear and culture (in addi-the Centre’s medical staff to have a definite radio-
tion, from three months onwards, a pair of laryngealgraphic extension of the tuberculous lesion at any
swabs by culture), and (d) tests of sensitivity toexamination subsequent to the first monthly exa-
isoniazid on one positive culture. mination was shown to an independent assessor,
Tomograms were taken at the end of one yearDr K. S. Sanjivi, who was unaware of the treatment
and the rate of inactivation of isoniazid was de-the patient was receiving. He decided whether or not
termined again. the new lesion warranted a change of chemotherapy.
FIG. 1
DIAGRAMMATIC REPRESENTATION OF THE FREQUENCY OF PERIPHERAL NEUROPATHY AND THE SEQUENCE
OF CHANGE OF PROPHYLACTIC AND THERAPEUTIC SUPPLEMENTS
Rate of
inactivation
Prophylactic
supplements
Cases of peripheral
neuropathy
Therapeutic
supplements
WHO 3006
aFor the full constituents of Aneurin. Co. and B-complex, see pages 457 and 456.
The two cases of peripheral neuropathy among the rapid inactivators (Aneurin. Co. and calcium series) were not confirmed
by the assessor until the 12th month and so the supplement was not changed.
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Serious clinical deterioration was regarded as aextent which warranted a change of chemotherapy,
ground for changing the chemotherapy without re-the isoniazid and supplements were continued un-
course to the independent assessor. changed, and in addition 1 g of streptomycin daily,
Change of chemotherapy
intramuscularly, for six days a week and 1-1.5 g of
pyrazinamide daily by mouth (approximately 30 mg/
If the pulmonary tuberculosis progressed to ankg body-weight) were given.
III. BACTERIOLOGICAL AND ASSAY PROCEDURES
EXAMINATION OF SPUTUM SPECIMENS AND LARYNGEAL
SWABS; SENSITIVITY TESTS
The methods used to examine sputum specimens
and laryngeal swabs and to determine the sensitivity
of cultures to isoniazid and streptomycin have been
described in detail elsewhere (Tuberculosis Chemo-
therapy Centre, 1959). In brief, the smears were
examined by fluorescence microscopy and were
graded as 3-plus, 2-plus, 1-plus and negative.
Sputum specimens were cultured, after treatment
with 4% NaOH, on Löwenstein-Jensen medium
which did not contain potato starch (Jensen, 1955).
Tests’ of sensitivity to isoniazid were performed by
inoculating a suspension of growth on to slopes of
Lowenstein-Jensen medium containing 0.2, 1, 5, and
50 µg/ml of isoniazid and on to a control slope con-
taining no isoniazid. The standard sensitive strain
H37Rv was also set up with each batch of tests as
a control.
DEFINITIONS OF BACTERIAL RESISTANCE TO ISONIAZID
In the following definitions of isoniazid resistance
growth has been defined as 20 or more colonies.
Pretreatment tests
Resistance was defined as:
(a) growth on 1 µg/ml or a higher concentration
even if the result of a test on a second culture was
sensitive; or   
(b) growth on 0.2 µg/ml, followed by growth on
the same or a higher concentration at a repeat test
on the same culture, even if the result of a test on a
second culture was sensitive; or
(c) growth on 0.2 µg/ml for two separate cultures,
irrespective of the results of any repeat test.
Tests during treatment
Cultures isolated during treatment were regarded
as resistant if growth occurred on 0.2 µg/ml or a
higher concentration of isoniazid, irrespective of the
results of repeat tests.
SERUM ISONIAZID ASSAY
The rate of inactivation of isoniazid was deter-
mined for each patient before treatment, and again
in the last month of treatment, after withdrawal of
all drugs for two days prior to the test. A test dose
of isoniazid (nominally 3 mg/kg body-weight) 1 was
given intramuscularly, and four-and-a-half hours
later a sample of blood was taken and the concentra-
tion of isoniazid in the serum was measured by micro-
biological assay (Gangadharam et al., 1961).
If the mean serum concentration of the two tests
(or, in five patients, the result of the only test per-
formed) was 0.69 µg/ml or greater the patient was
classified as a slow inactivator; if it was less than
0.49 µg/ml the patient was classified as a rapid in-
activator. No patient had a mean serum concentra-
tion between these levels.
IV. PATIENTS ADMITTED TO THE STUDY
Fifty-six patients were admitted to the study;plements as their index cases. There were 21 (38%)
50 were allocated at random to one of the three sup-slow and 35 (62%) rapid inactivators of isoniazid.
plements (Tab. Aneurin. Co., glutamic acid, and
calcium gluconate). The remaining six were con-
1 An assay of the isoniazid content of the solution con-
tained in a sample of ampoules taken from the batch in use
tacts of six of these patients and were prescribed theshowed this to be about 15% less than that stated on the
same high dosage of isoniazid and the same sup-
labels. Making allowance for this reduction in dosage did
not affect the classification of any patient.
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V. ISONIAZID TOXICITY
This section describes the toxic effects of high-
dosage isoniazid. One patient (rapid inactivator) has
been excluded because he had previously received
isoniazid plus PAS for eight months; his progress is
described on page 462. Of the remaining 55 patients
13 developed peripheral neuropathy during the
year; three of these also had cerebral symptoms–
convulsions in two and a toxic psychosis in the third.
Another patient had convulsions without evidence of
peripheral neuropathy.
There was no history of exposure to neurotoxic
substances other than isoniazid in any of these
patients except one, who developed peripheral neuro-
pathy and a toxic psychosis and who was known to
have a supply of methyl alcohol (see below). There
was no evidence of consumption of alcohol (pro-
hibited by law in Madras State since 1948) by any
other patient in this series.
PERIPHERAL NEUROPATHY
Age and sex
Of the 15 patients aged 35 or more, five (33%)
developed peripheral neuropathy, as compared with
eight (20%) of the 40 patients under 35 years of age.
Peripheral neuropathy occurred in 24% of 29 males
and 23% of 26 females.
Rate of inactivation of isoniazid
Eleven (52%) of the 21 slow inactivators of
isoniazid, as compared with only two (6%) of the
34 rapid inactivators, developed peripheral neuro-
pathy-a highly significant difference (P<0.001).
This difference was present in each of the three
series (see Fig. 1).
Time of onset
Of the 13 patients six first complained of symptoms
suggestive of neuropathy in the second month, two
in the third, four in the fourth and one in the fifth.
(The two rapid inactivators first developed their
symptoms in the fourth and fifth months, res-
pectively.)
Clinical features
The clinical features were similar in the three
series and closely resembled those observed pre-
viously at the Centre and described by Devadatta et
al. (1960). The earliest symptoms were variously
described as burning, pricking pain, numbness or
tingling of the feet; in a few patients the hands were
also affected. The earliest signs elicited were usually
los  of vibration sense in the toes and loss of ankle
jerks. Both these signs were present in 11 of the 13
patients at the time of diagnosis.
Psychosis
OTHER TOXIC EFFECTS
One patient (calcium, slow inactivator) developed
peripheral neuropathy in the second month and his
supplement was therefore changed to Tab. Aneurin.
Co. Despite this he deteriorated mentally in the
third month and became listless and withdrawn.
His supplement was changed again, from Tab.
Aneurin. Co. to vitamin B complex, and the iso-
niazid was continued; he became mentally normal
in about two months. This patient was found on
several occasions by the health visitor to have methyl
alcohol in his home; however, isoniazid was probably
the exciting cause of the neurotoxic changes since
the onset of the symptoms occurred soon after the
start of treatment with isoniazid.
Convulsions
Three patients, none of whom gave a history of
previous epilepsy, had epileptiform seizures probably
attributable to isoniazid toxicity. They complained
of a feeling of giddiness for a period of about one
hour before the seizures, which occurred between
five and 12 hours after taking a dose of isoniazid.
One patient (Aneurin. Co., slow inactivator) had
a number of attacks in the first three months of
treatment.Another patient (Aneurin. Co., rapid
inactivator) had one attack two days after the start
of chemotherapy and another in the eleventh month.
The third patient (calcium, rapid inactivator) had a
single seizure in the sixth month of treatment. The
first two patients also developed peripheral neuro-
pathy, the symptoms first occurring in the second
and fourth months, respectively.
The first patient had no more seizures when his
supplement was changed from Tab. Aneurin. Co.
to vitamin B complex even though the isoniazid
was continued. The supplements were not changed
in the other two patients as they had only isolated
attacks.
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VI. PREVENTION AND TREATMENT OF PERIPHERAL NEUROPATHY
Of the 56 patients 18 were given Tab. Aneurin. Co.
(Aneurin Co. series), 19 glutamic acid (glutamic
series), and 19 calcium gluconate (calcium series).
One patient (calcium) was excluded from the ana-
lysis below because he had previously been treated
with isoniazid.
PRETREATMENT COMPARISON OF THE THREE
SUPPLEMENT SERIES
In order to assess the effectiveness of the supple-
ments in preventing isoniazid toxicity, it is necessary
to verify that the three series were similar at the
start of treatment. The distributions of estimated
age were closely similar, the proportion of patients
over 35 years of age being 28% in the Aneurin. Co.
series, 27% in the glutamic series and 28 % in the
calcium series. The distributions of sex, general con-
dition and weight were also similar. Further, the
proportions of slow and rapid inactivators of iso-
niazid were similar: six (33%) of the Aneurin. Co.
series, seven (37%) of the glutamic series and eight
(44%) of the calcium series were slow inactivators.
EFFECT OF THE SUPPLEMENTS
Prophylactic effect
Peripheral neuropathy occurred in five (28%) of
the 18 patients in the Aneurin. Co. series, two
(11%) of the 19 patients in the glutamic series and
six (33%) of the 18 patients in the calcium series
who were included in the analysis (Fig. 1). Although
these differences are not statistically significant,
there is some evidence that glutamic acid may have
reduced the frequency of peripheral neuropathy but
there is no evidence that Tab. Aneurin. Co. did so.
Therapeutic effect
According to the plan of the study the 13 patients
who developed peripheral neuropathy were all
eligible for a change of supplement, but in two the
diagnosis was confirmed by the assessor so late in
the year that the supplement was changed in only
11. Seven patients (two glutamic, five calcium) had
their original supplement changed to Tab. Aneurin.
Co., in twice the prophylactic dosage; four patients
(Aneurin. Co.) had their original supplement
changed to vitamin B complex.
Tab. Aneurin. Co. Seven of the patients with
peripheral neuropathy were given Tab. Aneurin. Co.
therapeutically as the firstchange; five of these
showed progression of the symptoms and signs of
the neuropathy and their supplement was therefore
changed again to vitamin B complex after intervals
of 10, 19, 36, 37 and 66 days, respectively. The
neuropathy did not progress in the remaining two
patients, but in one of them the supplement wds
changed to vitamin B complex at 29 days because he
developed a psychosis believed to have been due to
isoniazid. The other patient improved symptoma-
tically, but there was no change in the physical signs.
Tab. Aneurin. Co. was thus of little effect in
reventing the progression of the peripheral neuro-
pathy when given in twice the dosage used for
prophylaxis.
Vitamin B complex. In all, nine patients were
given vitamin B complex therapeutically, four as
the first change of supplement when they had
developed peripheral neuropathy while on Tab.
Aneurin. Co. prophylactically and five (two glutamic,
three calcium) as the second change of supplement
because their neuropathy was progressing after the
first change, which had been to Tab. Aneurin. Co.
therapeutically (Fig. 1). In eight of the nine patients
the symptoms improved, four showing regression
of physical signs by the end of the year. The remain-
ing patient, after three weeks on vitamin B complex,
showed progression of the symptoms and signs; the
isoniazid was therefore stopped and the patient
received streptomycin and PAS, together with 300 mg
of pyridoxine daily in addition to the vitamin-B-
complex preparation.
It may be concluded that the vitamin-B-complex
preparation was effective in the treatment of iso-
niazid neuropathy, even when the isoniazid was
continued in high dosage.
The patient not included in the analysis of the effect of
supplements
As mentioned earlier, one patient (calcium) was
excluded from the analysis of the effect of supple-
m nts because it was found that he had had isoniazid
lus PAS for eight months three years previously.
Th re was therefore a remote possibility that this
might have predisposed him to develop peripheral
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neuropathy under further isoniazid treatment. ThisIn summary, there was no evidence that Tab.
patient received isoniazid (alone, as prescribed) inAneuri . Co. had an effect either in preventing the
the present study throughout the year. He developeddevelopment of peripheral neuropathy or in treating
peripheral neuropathy in the fifth month of treat-the condition once it had occurred. Glutamic acid
ment and was thereafter given Tab. Aneurin. Co.may have had some effect in preventing peripheral
in the therapeutic dosage for the rest of the year;n uropathy, but it was not marked. Vitamin B
his symptoms improved, although his ankle jerkscomplex, on the other hand, was found to be
were subsequently lost. effective therapeutically.
VII. PROGRESS OF PULMONARY TUBERCULOSIS TREATED WITH HIGH-DOSAGE ISONIAZID
Of the 56 patients admitted to the study two (both
rapid inactivators) have been excluded from the
analysis of the response of pulmonary tuberculosis to
treatment with isoniazid; one patient, with an
isoniazid-sensitive strain, was excluded because he
had previously received isoniazid and PAS for eight
months and the other because the infecting strain of
Mycobacterium tuberculosis wa found to be re-
sistant to isoniazid. There are thus 54 patients with
tubercle bacilli sensitive to isoniazid prior to admis-
sion to the study who were available for analysis.
The assessments of the radiographic and bacterio-
logical condition of the patients on admission to
treatment are given in Table 2. There were seven
(13%) patients with extensive cavitation, 13 (24%)
with gross or extensive disease, and 34 (63%) with
more than three lung zones involved. The first or
only collection specimen of sputum was positive on
smear examination in 45 (83%) of the patients.
DEATHS
Three of the 54 patients died during the year.
Death was due to pulmonary tuberculosis in one
patient (glutamic), a female aged 27 years, who
deteriorated clinically and radiographically in the
second month. Her chemotherapy was changed but
she died in the fourth month, two days after a
spontaneous pneumothorax.
The other two patients died from non-tuberculous
causes. The first (calcium), a male aged 25 years,
died of intracranial bleeding following a mastoid-
ectomy for a non-tuberculous infection; he had just
completed two months’ treatment and had shown
favourable radiographic and bacteriological res-
ponse. The second (Aneurin. Co.), a female aged
45 years, died in the eleventh month. The last radio-
graph showed considerable improvement of her ini-
tial small right apical lesion and all the cultures were
negative from the first month. However, she became
progressively weaker from the ninth month, but
would not agree to enter hospital for further
investigations. Her death was attributed to a non-
TABLE 2
RADIOGRAPHIC AND BACTERIOLOGICAL CONDITION
ON ADMISSION
Assessment on admission
to treatment
Extent of cavitation:
Nil
Slight
Moderate
Extensive
All patients
No. %
6 11
12 22
29 54
7 13
Total extent of disease:
Trivial or slight
Limited or moderate
Extensive or gross
3 6
38 70
13 24
Number of lung zones involved in
disease:
1,2or3
4, 5 or 6
Bacterial content of sputum: a
Direct smear negative
Direct smear positive:
1-plus (scanty)
9 17
9 17
2-plus (moderate) 28 52
3-plus (heavy) 8 15
Total patients 54 100
a First or only collection specimen.
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tuberculous cause but its exact nature was not estab-
lished. Permission for an autopsy was refused.
CHANGE OF CHEMOTHERAPY DUE TO RADIOGRAPHIC
DETERIORATION
Three patients had a change of chemotherapy, in
the eighth, ninth and tenth months, respectively,
because of radiographic deterioration confirmed by
an independent assessor. No patient had a change of
chemotherapy on grounds of clinical deterioration
alone.
CHANGE OF CHEMOTHERAPY DUE TO TOXICITY
One patient (Aneurin. Co. series), a slow inacti-
vator, developed severe and rapidly progressive
peripheral neuropathy in the third month (see
page 462); the isoniazid was replaced by streptomycin
and PAS.
PRESENTATION OF THE RESULTS FOR THE PATIENTS
WHOSE CHEMOTHERAPY WAS CHANGED OR WHO DIED
As in a previous ‘report (Tuberculosis Chemo-
therapy Centre, 1960) patients whose chemotherapy
was changed on account of deterioration of their
 disease or who died of tuberculosis remain in the
analyses for the rest of the year, whereas patients
whose chemotherapy was changed on account of
toxicity or who died from a non-tuberculous cause
have been excluded from the tables thereafter.
RADIOGRAPHIC CHANGES
As in an earlier study (Tuberculosis Chemotherapy
Centre, 1960), the radiographic changes were evalu-
ated by an independent assessor, Dr Raj Narain, who
was unaware of the treatment which any patient had
received. In brief, the changes were assessed for the
first six months and for the year, and four grades
were used to classify improvement-namely, excep-
tio al, considerable, moderate or slight. The findings
are set out in Table 3. During the first six months of
chemotherapy 33 (63%) of 52 patients showed
moderate or greater improvement. Over the full
12 months 37 (73%) of 51 patients showed moderate
or greater improvement, while two (4%) showed
radiographic deterioration and four (8%) either had
their treatment changed because of radiographic
deterioration or died of tuberculosis.
The changes in cavitation for the 12-month period
were also assessed by Dr Raj Narain; cavitation
disappeared in 30 (67%) and was less in six (13%) of
45 patients with initial cavitation.
SMEAR AND CULTURE RESULTS
The smear and culture results of the first or only
collect on specimen of sputum at 3-monthly intervals
are given in Table 4. There was a sharp decline in
the proportion of patients with positive cultures dur-
ing he early months of treatment; at three months
69% of 49 patients and at six months 75% of 51
patients had a negative culture. There was little
TABLE 3
Period
a Two separate assessments on standard radiographs.
b Excluding one patient who died in the third month of a non-tuberculous condition and one patient who had his chemotherapy
changed in the third month on account of toxicity.
c Excluding one patient who died in the eleventh month of a non-tuberculous condition.
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TABLE 4
PRESENCE OF TUBERCLE BACILLI IN SINGLE COLLECTION SPECIMENS OF SPUTUM
TAKEN FROM PATIENTS AT 3-MONTHLY INTERVALS
Total
patients
with culture
results a
54
49
51
51
50
– 45 5
0 10 5
0 8 4
2 7 4
3 6 3
Culture
negative b
No. %
4 7
34 69
38 75
37 7 3
37 7 4
a Patients who died of non-tuberculous conditions are excluded after their death and the patient
who had his chemotherapy changed on account of toxicity is excluded after the change. Patients
who died of tuberculosis or who had their chemotherapy changed owing to deterioration remain
in the totals throughout.
b Even if the smear was positive.
change during the rest of the year and at 12 months
the proportion of patients with a negative culture
was 74%.
The average number of specimens examined for
each patient monthly ranged from 2.6 to 2.9. The
percentage of patients with at least one positive
culture result at each month is shown in Fig. 2.
ISONIAZID SENSITIVITY
Tests of sensitivity to isoniazid were carried out
each month on one positive culture from each patient.
At one month four of 37 patients for whom sensi-
FIG. 2
PERCENTAGE OF PATIENTS EACH MONTH WITH AT
LEAST ONE POSITIVE CULTURE RESULT FROM MULTIPLE
BACTERIOLOGICAL SPECIMENS
tivity e t results were available had a resistant cul-
ture; at three, six, nine and 12 months 16 of 19, all
of 11, 10 of 11, and six of seven, respectively, had a
resistant culture. The only patient with an isoniazid-
sensitive culture at 12 months had had a bacteri-
ol gical relapse with sensitive organisms at nine
months. He had been exceedingly irregular in drug
taking after the third month, 47 out of a total of
55 urine tests being negative for isoniazid.
RESPONSE TO TREATMENT DURING THE 12 MONTHS
Table 5 presents a classification of all the patients
at 12 months, based primarily on the bacteriological
response to treatment. In all, 37 (73%) of 51 patients
had bacteriologically quiescent disease; this includes
two patients who had disease of bacteriologically
doubtful status which previous studies have shown
can be regarded as quiescent disease (Velu et al.,
1960, 1961). Of the 35 patients with quiescent
disease, 32 remained persistently culture-negative
from the fourth month.
PATIENTS NOT INCLUDED IN THE ANALYSIS OF THE
RESPONSE TO TREATMENT
As mentioned earlier, two patients were excluded
from the analysis of the response to treatment.
One had a primarily isoniazid-resistant infection of
high degree (minimal inhibitory concentration
greater than 50 µg/ml) and the other had received
chemotherapy for more than two weeks before
admission. Both patients had quiescent disease at
one year.
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VIII. RESPONSE TO TREATMENT RELATED TO VARIOUS FACTORS ON ADMISSION
TO TREATMENT
With regard to the relation between pretreatment
condition and response to treatment, four (57%) of
seven patients with extensive cavitation showed an
unfavourable response to treatment (bacteriologi-
cally relapsed or active disease, change of chemo-
therapy owing to deterioration, or death from
tuberculosis), as compared with seven (25%) of 28
with moderate, one of 10 with slight and two of six
with no cavitation. Five (42%) of 12 patients with
disease graded as extensive or gross showed an
unfavourable response,as compared with nine
(23 %) of 39 with less extensive disease. In respect
of the number of lung zones involved in disease, 11
(34%) of 32 patients with four or more zones in-
volved showed an unfavourable response, as com-
pared with three (16 %) of 19 with fewer zones
involved. In respect of the bacterial content of the
first or only collection specimen of sputum, 11 (3 1%)
of 35 patients with 2-plus or 3-plus smears showed an
unfavourable response, as compared with three
(19 %) of 16 with 1-plus or negative smears. It may
be concluded that patients with more serious disease
as measured by the radiographic extent of the lesion,
cavitation, and the bacterial content of sputum
more frequently showed an unfavourable response
to treatment than patients with less serious disease.
Of the 51 patients, 20 (39 %) were slow inactivators
of is n azid and 31 (61%) were rapid inactivators of
isoniazid. There were no important differences
between the slow and rapid inactivators in respect of
the radiographic condition of their disease or the
degree of sputum positivity on admission to treat-
men . An unfavourable response at 12 months
occurred in four (20%) of the 20 slow inactivators
and in 10 (32%) of the 31 rapid inactivators. This
difference does not, however, attain statistical
significance.
The response of the patients who developed
peripheral neuropathy was similar to that of the
patients who did not. Of the 13 patients who
developed peripheral neuropathy, one was taken off
isoniazid in the third month on account of severe
toxicity (see page 462) and the response to isoniazid
treatm nt of his pulmonary tuberculosis cannot be
assessed. Of the remaining 12 patients, three (25 %)
had an unfavourable response to treatment, as
compared with 11 (28 %) of the 39 patients who did
not develop peripheral neuropathy.
IX. COMPARISON OF RESPONSE WITH HIGH AND MODERATE DOSAGE OF ISONIAZID
The response to treatment of the 54 patients in the
present study who received the high dosage of 12.5-
15.2 mg/kg body-weight of isoniazid (650 mg for a
100-lb. patient) once daily may be compared with
the results in 70 patients in a previous investigation
(Tuberculosis Chemotherapy Centre, 1960), who
received the moderate dosage of 7.8-9.6 mg/kg body-
weight (400 mg for a 100-lb. patient) once daily (HI-l
series). Although the two series of patients were not
treated concurrently, they were drawn from the same
poor urban community and the same criteria of
eligibility for admission to the studies were adopted.
Moreover, all the radiographic assessments were
made by the same independent assessor, and the
same bacteriological procedures were followed. How-
ever, in order to see whether the comparison is valid
it is essential to determine whether the condition of
the patients before treatment in the two series was
similar. Most of the patients were between 15 and
44 years of age (87 % in the present series and 93 % in
the HI-1 series). An analysis of general condition
and weight (not presented here) showed that there
were no important differences between the two
series. Table 6 shows a comparison of the pre-
treatment radiographic and bacteriological con-
dition i  the two series. Cavitation was graded as
extensive in 13 % of the 54 patients in the present
series and in 10% of the 70 in the HI-1 series; how-
ever, 11% and 1%, respectively, had no cavitation.
The distributions of the extent of radiographic
disease and of the number of lung zones involved in
disease were the same. The first or only collection
specimen of sputum was negative on smear in 17 %
and 9%, respectively; 3-plus positive smears were
obtained in 15% and 40%; respectively. In the
present series 39% were slow inactivators, as com-
pared with 53 % of the HI-1 series.
In summary, the present series was at an advan-
tage in respect of the extent of cavitation and the
bacterial content of the sputum, but at a possible
disadva tage in having fewer slow inactivators of
isoniazid (Selkon et al., 1961).
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TABLE 5
CLASSIFICATION OF ALL THE PATIENTS AT THE END
OF 12 MONTHS ACCORDING TO THEIR RESPONSE
TO TREATMENT
TABLE 6
RADIOGRAPHIC AND BACTERIOLOGICAL CONDITION
ON ADMISSION TO TREATMENT OF PATIENTS IN THE
PRESENT SERIES (12.5-15.2 mg/kg) AND IN THE HI-1
SERIES a (7.8-9.6 mg/kg)
All patients
Classification at the end of 12 months Present
series HI-l series
No. %
1 I
26 37
36 51
7 10
Assessment on admission
to treatment
Extent of cavitation:
Nil
Slight
Moderate
Extensive
Total extent of disease:
Trivial or slight
Limited or moderate
Extensive or gross
Number of long zones involved in
disease:
1, 2 or 3
4, 5 or 6             
Bacterial content of sputum: b
Direct smear negative
Direct smear positive:
1-plus (scanty)
2-plus (moderate)
3-plus (heavy)
Total patients
No. %
No. %
6 11
12 22
29 54
7 13
7
16
4
5
0
0
0
1
1
1
3 6 4 6
38 7 0 49 7 0
13 2 4 17 2 4
Total patients with bacteriologically quiescent
disease . . . . . . 35 6 9
Patients with disease of bacteriologically doubt-
ful status:
that is, patients whose cultures were all
negative at three or more consecutive
monthly examinations but who produced
an isolated positive culture at one of the
last three monthly examinations-i.e., at
10, 11 or 12 months . . . . . . . .
20 3 7 26 3 7
34 6 3 44 6 3
9 17
9 17
28 5 2
8 15
54 100
6
19 2 7
17 2 4
28 4 0
70 100
2 4
Patients with bacteriologically relapsed disease:
that is, patients whose cultures were all
negative at three or more consecutive
monthly examinations, but who produced
two or more positive cultures in the last
three monthly examinations–i.e., at 10, 11
and 12 months . . . . . . 1 2
Patients with bacteriologically active disease:
that is, (a) patients whose cultures were never
all negative at three consecutive
monthly examinations . . . . . .
or (b) patients who deteriorated and had
their chemotherapy changed .
a Tuberculosis Chemotherapy Centre (1960).
b First or only collection specimen.
9 18
3 6
1 2
RESULTS AT 12 MONTHS
Results at 12 months are available for 51 of the
54 patients in the present series (two non-tuberculous
deaths and one change of chemotherapy on account
of toxicity being excluded) and for 64 of the 70
patients in the HI-1 series (one non-tuberculous
death and five changes of chemotherapy on account
of toxicity being excluded).
Radiographic changes
Considering the radiographic changes during the
12 months (Table 7), 88 % of the present series
showed radiographic improvement, as compared
with 86 % of the HI-1 series.
Tuberculous death . . . . .
Total patients with unfavourable response . 14 2 7
51 100Total . . . . . . . . . . .
Patients who had their chemotherapy changed
on account of toxicity . . . . . . 1 –
Non-tuberculous deaths . . . . . . . 2  –
54               –All patients . . . . . . . . . . . .
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TABLE 7
RADIOGRAPHIC AND BACTERIOLOGICAL RESPONSES IN THE PRESENT (12.5-15.2 mg/kg) AND IN THE HI-1 SERIESa
(7.6-9.6 mg/kg)
Treatment’ Total
series patients
Present  51c
HI-1 64 d
Radiographic response at 12 months
No. %  No. %  No. %  No. %
45 88 0 0 2 4  4 8
55 86 4 6  0 0  5 8
Bacteriological status at 12 months
No. %  No. %  No. %
37 73 10 20 4 8
47 73 12 19 5 8
a Tuberculosis Chemotherapy Centre (1960).
b Including disease of bacteriologically doubtful status.
c Excluding two patients who died of non-tuberculous conditions and one patient who had his chemotherapy changed on
account of toxicity.
d Excluding one patient who died of a non-tuberculous condition and five patients who had their chemotherapy changed on
account of toxicity.
Cavitation changes
Cavitation disappeared in 30 (67 %) of 45 patients
in the present series and in 39 (62%) of 63 in the
HI-1 series.
Bacteriologically quiescent disease
Table 7 shows that the proportions with bacteri-
ologically quiescent disease at 12 months were
the same–73% in each series. When statistical
standardization for the pretreatment differences in
the rate of inactivation of isoniazid, the extent of
cavitation, and the bacterial content of sputum was
undertaken, the standardized proportions of patients
with quiescent disease were 73% for the present
series and 72% for the HI-1 series.
In summary, there was little difference in the
response to treatment with isoniazid in high and in
moderate dosage.
X. SELF-ADMINISTRATION OF ISONIAZID AND THE SUPPLEMENTS
The importance of taking the tablets regularly was
impressed on the patients both before and through-
out the period of treatment.Two methods were used
to assess the regularity with which they did so.
1. Specimens of urine were obtained from patients
during their regular visits to the Centre and at
surprise visits made to their homes. They were
tested for isoniazid by the combined N-M test
(Gangadharam et al., 1958).
2. The packets containing the tablets were
counted at surprise visits to the patients’ homes.
SENSITIVITY OF URINE TESTS
In order to evaluate the results of tests for iso-
niazid in the urine it was necessary to determine the
period over which the test would remain positive.
A series of 25 volunteers received isoniazid in a single
supervised dose of 13-15 mg/kg body-weight.
Specimens of urine were taken before the test dose
and 28, 48 and 52 hours afterwards. The specimens
were tested along with routine specimens in the
laboratory, the laboratory staff being unaware that a
special study was in progress.
Tests for isoniazid in the urine were positive in
two of the 25 specimens taken before the test dose, in
20 of 24 specimens tested at 28 hours, in seven of 24
at 48 hours and in three of 23 at 52 hours. Thus a
negative result for isoniazid in the urine indicated in
a large proportion of patients that the drug had not
been aken for at least 24 hours previously.
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RELATION BETWEEN REGULARITY OF SELF-
ADMINISTRATION OF ISONIAZID AND DEVELOPMENT OF
PERIPHERAL NEUROPATHY
Variations in the self-administration of isoniazid
could have affected the development of peripheral
neuropathy in several important ways, namely:
(a) Peripheral neuropathy might have occurred
only in those patients who took their isoniazid most
regularly.
(b) If the irregularity was greater in one series
than in others it might have affected the comparisons
between the series.
(c) If patients with peripheral neuropathy took
less isoniazid after the supplement was changed, the
therapeutic supplement might give a false appearance
of effectiveness.
These possibilities were examined on the basis of
the results of tests on the urine specimens obtained
at the Centre. The results of urine specimens
collected from the homes of patients have not been
considered for the reasons given in a previous report
(Tuberculosis Chemotherapy Centre, 1960).
Comparison of regularity of self-administration of
isoniazid in patients with and in patients without
peripheral neuropathy
For the 13 patients with peripheral neuropathy, all
of whom developed their first symptoms before six
months, the results of urine tests on clinic specimens
up to the time of onset of symptoms were compared
with those in the first six months for the 42 patients
without peripheral neuropathy. The proportions of
negative results were very similar: 13.2% of 150
tests were negative in the former group, as compared
with 14.7% of 1013 tests in the latter. (No relation-
ship was found between irregularity in drug taking
and the isoniazid inactivation state.)
Regularity of self-administration of isoniazid in the
three supplement series
Comparing the three supplement series, the pro-
portions of negative tests for isoniazid were 12.3% of
677 tests in the Aneurin. Co. series, 18.3% of 787
in the glutamic series and 21.6% of 611 in the calcium
series. For the patients with peripheral neuropathy,
only the clinic urine tests performed up to the time
of the first change of supplement have been included.
It is unlikely that these differences affected the
frequency of peripheral neuropathy in the three
series.
Regularity of self-administration of isoniazid after
change of supplement
There was no evidence from the results of urine
tests that the patients took their isoniazid less
regularly after changing from their prophylactic to
their therapeutic supplement.
In summary, there was no evidence that the degree
of irregularity in taking isoniazid materially affected
either the frequency of neuropathy in the three
supplement series or its progression.
REGULARITY OF SELF-ADMINISTRATION OF THE
SUPPLEMENTS
Variations in the self-administration of the supple-
me ts could also have affected the development of
peripheral neuropathy. In this study, packet counts
were the only means available for assessing the
regularity with which the supplements were taken.
The results of packet counts done up to the onset of
symptoms for the patients who developed peripheral
neuropathy were compared with those of the counts
done in the first six months for the patients who did
not develop peripheral neuropathy.
Prophylactic supplements
Surplus packets were found on 14.2% of 288
occasions on which counts were made at surprise
visits to the homes of patients who developed peri-
pheral neuropathy, as compared with 11.7% of 1980
occasions in the homes of patients who did not
develop peripheral neuropathy. This difference is
unlikely to have been of clinical importance.
Therapeutic supplements
There was no evidence from the packet counts of
individual patients that there was any difference in
the regularity with which the supplements were taken
after the change from a prophylactic to a therapeutic
supplement.
RELATION BETWEEN REGULARITY OF SELF-
ADMINISTRATION OF ISONIAZID AND RESPONSE TO
TREATMENT OF PULMONARY TUBERCULOSIS
Self-ad inistration of isoniazid
The results of tests done on specimens of urine
taken, during their visits to the clinic, from the 51
patients who completed one year of isoniazid
therapy are given in Table 8. The average number
of sp cimens collected per patient per month was
4.0 and was similar for males and females. The
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TABLE 8 TABLE 9
REGULARITY OF SELF-ADMINISTRATION OF ISONIAZID
(AS ASSESSED BY TESTS ON URINE SPECIMENS
OBTAINED AT ROUTINE VISITS TO THE CENTRE)
UNFAVOURABLE RESPONSE TO TREATMENT RELATED
TO THE PROPORTION OF NEGATIVE TEST RESULTS ON
URINE SPECIMENS OBTAINED AT ROUTINE VISITS
TO THE CENTRE
Total number of tests
Average number of test re-
sults per patient per month
Number of test results which
were negative
Percentage of test results
which were negative
27 24
1 281 1 064
4.0
221
17.3
3.9
155
14.6
Females Allpatients
4.0
376
16.0
a Excluding two patients who died from non-tuberculous
conditions and one who had his chemotherapy changed on
account of toxicity.
proportion of negative results was, on the average,
16.0%, being 17.3% for males and 14.6% for
females.
Response to treatment
Table 9 relates the percentage of negative urine
tests on clinic specimens to the frequency of un-
favourable response to treatment. The number of
patients showing an unfavourable response was four
(57%) of seven with no negative test results, as com-
pared with 10 (23 %) of 44 with one or more negative
results. The numbers showing unfavourable response
with different degrees of irregularity in taking
isoniazid were seven (24%) of 29 with 1-19 % negative
Percentage
of test results
which were negative
0 7
1-9 16
10-!9 13
20-49 11
50 or more 4
Total
patients a
Unfavourable
response b
No. %
4 (57) c
2 (12)
5 (36)
2 (18)
1 (25)
a Excluding two patients who died of non-tuberculous condi-
tions and one patient who had his chemotherapy changed on
account of toxicity.
b Defined as tuberculous death; bacteriologically active
disease at 12 months, including  change of chemotherapy owing
to deterioration; or bacteriologically relapsed disease at 12
C The parentheses indicate that the percentages are based
on fewer than 25 observations.
urine test results, and three (20 %) of 15 with 20%
or more negative results. An analysis, not shown
here, has revealed that this lack of association cannot
be accounted for by the fact that patients with serious
dis ase, and therefore a poor prognosis, took their
drugs more regularly than those with less extensive
di ease.
Ther  was thus no evidence that the degree of
irregularity in taking isoniazid encountered in this
study, as measured by urine tests, affected the res-
ponse to treatment.
XI. DISCUSSION
Since isoniazid is both the cheapest and the most
efficient drug available for the treatment of pulmo-
nary tuberculosis, it would be especially suitable for
use in developing countries if the results of treatment
with it alone were satisfactory. In a previous study
by the Centre (Tuberculosis Chemotherapy Centre,
1960), three regimens of isoniazid alone were com-
pared-namely, a moderate dosage (7.8-9.6 mg/kg
body-weight) given once daily, the same daily dosage
given in two doses, and a small daily dosage (3.9-
5.5 mg/kg body-weight) given in two doses daily; it
was found that the moderate dosage given once daily
was superior to the other two regimens, but was
inferior to the much more expensive combination of
isoniazid and PAS. This made it desirable to test the
effect of an even larger amount of isoniazid given
alone in a single daily dose.
A preliminary investigation (unpublished) sug-
g sted that the highest single daily dose of isoniazid
that could be given without producing signs of acute
int lerance, such as vomiting and tachycardia, was
approximately 15 mg/kg body-weight. Thus a dosage of
12.5-15.2mg/kg body-weight daily (650mg for a patient
weighing 100 lb.) was chosen for the present study.
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Unfortunately, even a moderate dosage of iso-
niazid may lead to peripheral neuropathy, and
although pyridoxine is reported to be effective in the
prophylaxis of this condition it has certain draw-
backs, for the generally accepted dosage of 100 mg
or more daily greatly increases the cost of treatment.
Moreover, it has been suggested that pyridoxine may
interfere with the antituberculous properties of
isoniazid (Biehl & Vilter, 1954; East African/British
Medical Research Council Isoniazid Investigation,
1960), and there is experimental evidence (McCune,
Deuschle & McDermott, 1957) to support this sug-
gestion. Because of these disadvantages other sub-
stances, reported to be of use in the management of
isoniazid toxicity, were tested.
A vitamin-B-complex preparation, similar to
Tab. Aneurin. Co., containing no pyridoxine had
been reported in 1958 by Turner (personal com-
munication, subsequently published in 1961) to be
of use in the treatment of peripheral neuropathy in
East Africa even when high-dosage isoniazid
(1000 mg) was continued. Another, more compre-
hensive B-complex preparation, containing only a
small amount of pyridoxine, had been used with
success in the treatment of isoniazid neuropathy at
the Centre (Devadatta et al., 1960). Glutamic acid
had been used with good effect prophylactically by
Almeida et al. (1960)-a finding which has important
implications in relation to the mechanism of produc-
tion of peripheral neuropathy. The present investiga-
tion was intended as a pilot study to assess the value
of Tab. Aneurin. Co. and glutamic acid in the
prevention of isoniazid neuropathy, and a larger
dosage of Tab. Aneurin. Co. and the more compre-
hensive B-complex preparation in the trea ment of
the condition, and also to obtain a provisional
assessment of the therapeutic efficacy of a single high
daily dose of isoniazid–namely, 12.5-15.2 mg/kg
body-weight.
EFFECT OF SUPPLEMENTS
There was no evidence that Tab. Aneurin. Co. had
an effect in preventing the development of peripheral
neuropathy since there were five cases among 18
patients on it, as compared with six cases among
18 patients on the placebo. In twice the dosage in
which it was used prophylactically, it failed in the
treatment of the neuropathy in five of the seven
patients who continued to receive the high dosage of
isoniazid. This finding differs from the observations
of Turner (1961), which were made on Africans in
Kenya, where the staple diet is different.
The more comprehensive vitamin B complex
(which contained the same three constituents as Tab.
Aneurin. Co.,in larger dosage, and also small
amounts of pyridoxine, panthenol and cyanocoba-
lamin) had a good therapeutic effect on the peripheral
neuropathy in eight of nine patients who continued
on t e isoniazid regimen; this confirms the findings
with the same preparation in an earlier study
(Devadatta et al., 1960). It may be inferred that this
vitamin preparation (or one of its constituents),
aving proved itself therapeutically, is likely to be
effective in the prevention of isoniazid neuropathy.
Glutamic acid may have had some effect in pre-
venting peripheral neuropathy, as the frequency of
the condition among those taking it was two out of
19, as compared with six out of 18 among the placebo
series. Even so, this supplement was not highly
effective as there was a frequency of over 10%, and
as it is also bulky and expensive, it is of little prac-
tical importance in the prevention of isoniazid neuro-
pathy. These findings support those of Tchertkoff et
al. (1956), who found that 10-12 g of glutamic acid
d ily (  dosage of the order of 150 mg/kg body-
weight) delayed but did not prevent the neuropathy
due to isoniazid given in a daily dosage of 25 mg/kg
b dy-weight; they differ, however, from those of
Almeida et al. (1960), who found that glutamic acid
in a d ily dosage of 200 mg/kg body-weight pre-
vented isoniazid neuropathy in patients receiving
isoniazid in a daily dosage of 20 mg/kg body-weight.
FREQUENCY OF ISONIAZID TOXICITY
Peripheral neuropathy was by far the most fre-
que t toxic effect attributed to isoniazid; it occurred
in 13 of the 55 patients. The frequency among slow
inactivators (52% of 21) was significantly greater
than that among rapid inactivators (6 % of 34), thus
confirming the observations of Devadatta et al.
(1960). It is of interest to consider the frequency of
peripheral neuropathy in slow inactivators un-
modified by prophylactic supplement in the present
and in an earlier study. In the present study there
were eight slow inactivators receiving placebo and
12.5-15.2 mg/kg isoniazid daily in one dose, and
five (62 %) developed isoniazid neuropathy. In a pre-
vious study peripheral neuropathy occurred in 11
(28 %) of 39 slow inactivators receiving 7.8-9.6 mg/kg
body-weight daily in one dose and in six (14%) of 44
slow inactivators receiving the same dosage given in
two doses, while no peripheral neuropathy occurred
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among 51 slow inactivators receiving 3.9-5.5 mg/kg
of isoniazid daily in two doses (Devadatta et al.,
1960). Thus, these findings suggest an association
between the dosage of isoniazid and the frequency of
neuropathy.
The onset of the neuropathy, as measured by the
first complaint of symptoms, occurred earlier with
the high dosage of isoniazid used in this study than
with the moderate dosage used in the earlier study.
In the present study, eight of 13 patients first
spontaneously complained of their symptoms within
three months of receiving a single daily dose of
12.5-15.2 mg/kg body-weight isoniazid, as compared
with four of 13 (11 slow and two rapid inactivators)
in the previous study on a single daily dose of
7.8-9.6 mg/kg body-weight; by the end of five
months all 13 patients in the present study, as
compared with nine of 13 in the earlier study, had
complained of symptoms. This earlier onset of
symptoms with higher doses of isoniazid has pre-
viously been reported by Biehl & Nimitz (1954).
However, even on the higher dosage of isoniazid
used in the present study the physical signs take
several weeks to develop; and if the patients with
suggestive symptoms are seen each week they can
readily be treated, and will come to no serious
harm.
Three (5%) of the 55 patients suffered from
generalized epileptiform convulsions and one from
a toxic psychosis. Manifestations of central nervous
system intoxication have been reported by others
(Tchertkoff et al., 1956; Organick, 1958; Turner,
1961). Since two of the patients with convulsions
were rapid inactivators of isoniazid, this complica-
tion does not appear to be closely related to the rate
of inactivation and may therefore be produced by a
different mechanism from that which produces
peripheral neuropathy. The toxic psychosis that
occurred in another patient, a slow inactivator, was
probably due to isoniazid, although methyl alcohol
may have played some part.
RESPONSE OF PULMONARY TUBERCULOSIS TO
TREATMENT WITH ISONIAZID IN HIGH DOSAGE
Since the primary object of the study was to
compare the effectiveness of various substances in
the prevention and treatment of isoniazid toxicity,
no concurrent comparison of the therapeutic effect of
the high-dosage isoniazid regimen with that of other
regimens was included. It is, however, possible to
make a comparison between the results obtained with
this high dosage (12.5-15.2 mg/kg body-weight) and
those obtained with a moderate dosage (7.8-9.6 mg/
kg body-weight) given in a single daily dose for one
year (Tuberculosis Chemotherapy Centre, 1960).
Although this was not a concurrent comparison with
random allocation, the patients in the two studies
were drawn from the same community and were
subject to the same criteria for admission. More-
over, the same radiographic and bacteriological
methods and standards were used throughout the
year in each study. Standardization for the small
pretreatment differences showed that, at one year,
73 % of the patients on the high dosage of isoniazid,
as compared with 72 % on the moderate dosage, had
attained bacteriological quiescence, and this is
ugge tive that raising the dosage of isoniazid from
7.8-9.6 mg/kg body-weight given in one dose to
12.5-15.2 mg/kg given in one dose does not increase
the therapeutic efficiency.
Because of the possible value of giving isoniazid
al ne in moderate dosage after an initial period of
combined treatment, the search for a cheap and
effective prophylactic against peripheral neuropathy
is being continued at the Centre. The findings
reported here do not make it clear whether the effect
of the vitamin B preparation was due solely to the
small amount of pyridoxine or whether other con-
stituents were wholly or in part responsible. This
problem is being investigated in another study, which
will also give further information on the therapeutic
effect of isoniazid in high dosage.
XII. SUMMARY
1. A total of 56 South Indian patients withniazid in high dosage. The mean daily dosage of
pulmonary tuberculosis was admitted to a studyisoniazid at the start of treatment was 13.8 mg/kg
designed to investigate the prevention and treatmentbody-weight (range, 12.5-15.2 mg/kg).
of isoniazid toxicity and to obtain preliminary2. Each patient received one of three randomly
information on the efficacy of treatment with iso-allocated supplementary regimens, namely :
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(a) Tab. Aneurin. Co. (British National Formulary ;
each tablet contained 1 mg of aneurine hydro-
chloride, 1 mg of riboflavine and 15 mg of nico-
tinamide) given as three tablets twice daily (18
patients);
b) l- glutamic acid, 0.5 g in each tablet, given as
five tablets twice daily (19 patients);
(c) Calcium gluconate, 0.5 g in each tablet, given
as five tablets twice daily (19 patients);
The trial was conducted on a “ double-blind ”
basis; the doctors did not know the dosage of iso-
niazid, the nature of the supplements given, or of
any subsequent change in them.
3. The analysis in the toxicity section of this
report concerns 55 patient–namely, 18 who
received Tab. Aneurin. Co., 19 who received
glutamic acid and 18 who received the placebo
calcium gluconate.
4. Isoniazid toxicity affected a total of 14 patients.
Of these, 13 had peripheral neuropathy (two also
had convulsions and a third a toxic psychosis). The
fourteenth patient had convulsions without evidence
of neuropathy.
5. The time of onset of peripheral neuropathy
ranged from the second to the fifth month of treat-
ment. It occurred in 52% of 21 slow inactivators of
isoniazid and in 6% of 34 rapid inactivators
(P<0.001).
6. Tab. Aneurin. Co. (British National For-
mulary) was ineffective in preventing peripheral
neuropathy, which occurred in five (28%) of 18
patients receiving this supplement, as compared
with six (33%) of 18 patients receiving calcium
gluconate. Used in twice the prophylactic dose it
did not prevent the progression of the neuropathy
in five out of seven patients.
7. The glutamic acid appeared to have some
prophylactic effect, since peripheral neuropathy
occurred in two (11%) of 19 patients receiving this
supplement, as compared with six (33 %) of 18
patients receiving calcium gluconate; but this
difference does not attain statistical significance.
8. Nine patients were treated with vitamin B
complex given as three tablets twice daily. The daily
dosage of the constituents was: 60 mg of aneurine
hydrochloride, 30 mg of riboflavine, 300 mg of
nicotinamide, 6 mg of pyridoxine, 18 mg of pan-
thenol and 6 µg of cyanocobalamin. Improvement
occurred in eight patients. It is uncertain whether
the small dose of pyridoxine was solely responsible
for the effectiveness of this vitamin-B-complex
preparation and this point will be the subject of
further investigation.
9. The analysis of the response of pulmonary
tuberculosis to treatment concerns 51 patients all of
whom had organisms sensitive to isoniazid on
admission.
10. At the end of one year, cavitation had
disappeared in 30 (67%) of 45 patients with initial
cavitation, and 37 (73%) of the 51 patients showed
moderate or greater radiographic improvement;
35 (69%) had bacteriologically quiescent disease and
two (4%) had disease of bacteriologically doubtful
status. Such bacteriological responses occurred in
16 (80%) of 20 slow inactivators and 21 (68%) of 31
rapid inactivators.
11. The response of the pulmonary tuberculosis
of 51 patients in the present study who received
isoniazid in high dosage has been compared with
that of 64 patients in a previous study who received
a single daily dose of isoniazid of 7.8-9.6 mg/kg
body-weight.
12. Over the 12-month period the response to
treatment in the two series was similar. Thus,
radiographic improvement occurred in 88% and
86 %, respectively. Clinical or radiographic detiora-
tion or death from tuberculosis occurred in 8% in
both series. Cavitation had disappeared by 12
months in 67% of 45 patients in the present series
and in 62% of 63 patients in the previous series.
At 12 months the standardized proportion of
patients whose disease was bacteriologically quiescent
wa  73% and 72%, respectively. Thus it appears
that raising the dosage of isoniazid from 7.8-9.6
mg/kg to 12.5-15.2 mg/kg body-weight did not
materially affect the therapeutic response.
13. In conclusion, this study has shown: (a) that
a vitamin B preparation which did not contain
pyridoxine was ineffective in preventing peripheral
neuropathy due to a high dosage of isoniazid, while
glutamic acid may have had some effect; (b) that a
B-complex preparation containing a daily dosage of
only 6 mg of pyridoxine was effective in the treat-
m nt of the condition while the high dosage of
isoniazid was continued; (c) that it was unlikely that
increasing the single daily dosage of isoniazid from
7.8-9.6 mg/kg to 12.5-15.2 mg/kg body-weight
alt red the therapeutic response.
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